S&P 500   3,325.72 (+0.12%)
DOW   29,176.62 (-0.03%)
QQQ   224.52 (+0.29%)
AAPL   319.33 (+0.51%)
FB   220.37 (-0.43%)
MSFT   166.42 (+0.43%)
GOOGL   1,488.54 (+0.29%)
AMZN   1,889.35 (+0.10%)
CGC   24.44 (+1.33%)
NVDA   253.01 (+1.18%)
BABA   219.87 (-1.12%)
MU   59.29 (+0.20%)
GE   11.81 (+3.87%)
TSLA   571.10 (+0.27%)
AMD   51.67 (+0.47%)
T   38.66 (-0.97%)
ACB   2.06 (+0.98%)
F   9.14 (-0.33%)
NFLX   345.32 (+5.93%)
DIS   142.37 (-1.14%)
S&P 500   3,325.72 (+0.12%)
DOW   29,176.62 (-0.03%)
QQQ   224.52 (+0.29%)
AAPL   319.33 (+0.51%)
FB   220.37 (-0.43%)
MSFT   166.42 (+0.43%)
GOOGL   1,488.54 (+0.29%)
AMZN   1,889.35 (+0.10%)
CGC   24.44 (+1.33%)
NVDA   253.01 (+1.18%)
BABA   219.87 (-1.12%)
MU   59.29 (+0.20%)
GE   11.81 (+3.87%)
TSLA   571.10 (+0.27%)
AMD   51.67 (+0.47%)
T   38.66 (-0.97%)
ACB   2.06 (+0.98%)
F   9.14 (-0.33%)
NFLX   345.32 (+5.93%)
DIS   142.37 (-1.14%)
S&P 500   3,325.72 (+0.12%)
DOW   29,176.62 (-0.03%)
QQQ   224.52 (+0.29%)
AAPL   319.33 (+0.51%)
FB   220.37 (-0.43%)
MSFT   166.42 (+0.43%)
GOOGL   1,488.54 (+0.29%)
AMZN   1,889.35 (+0.10%)
CGC   24.44 (+1.33%)
NVDA   253.01 (+1.18%)
BABA   219.87 (-1.12%)
MU   59.29 (+0.20%)
GE   11.81 (+3.87%)
TSLA   571.10 (+0.27%)
AMD   51.67 (+0.47%)
T   38.66 (-0.97%)
ACB   2.06 (+0.98%)
F   9.14 (-0.33%)
NFLX   345.32 (+5.93%)
DIS   142.37 (-1.14%)
S&P 500   3,325.72 (+0.12%)
DOW   29,176.62 (-0.03%)
QQQ   224.52 (+0.29%)
AAPL   319.33 (+0.51%)
FB   220.37 (-0.43%)
MSFT   166.42 (+0.43%)
GOOGL   1,488.54 (+0.29%)
AMZN   1,889.35 (+0.10%)
CGC   24.44 (+1.33%)
NVDA   253.01 (+1.18%)
BABA   219.87 (-1.12%)
MU   59.29 (+0.20%)
GE   11.81 (+3.87%)
TSLA   571.10 (+0.27%)
AMD   51.67 (+0.47%)
T   38.66 (-0.97%)
ACB   2.06 (+0.98%)
F   9.14 (-0.33%)
NFLX   345.32 (+5.93%)
DIS   142.37 (-1.14%)
Log in

NASDAQ:IART - Integra Lifesciences Stock Price, Forecast & News

$56.45
-1.95 (-3.34 %)
(As of 01/23/2020 03:36 PM ET)
Add
Compare
Today's Range
$56.25
Now: $56.45▼
$58.47
50-Day Range
$56.81
MA: $59.33▼
$62.27
52-Week Range
$45.07
Now: $56.45▼
$65.09
Volume205,949 shs
Average Volume353,297 shs
Market Capitalization$4.85 billion
P/E Ratio81.81
Dividend YieldN/A
Beta1.1
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IART
Previous Symbol
CUSIP45798520
CIK917520
Webhttp://www.integralife.com/
Phone609-275-0500

Debt

Debt-to-Equity Ratio1.07
Current Ratio2.92
Quick Ratio1.92

Price-To-Earnings

Trailing P/E Ratio81.81
Forward P/E Ratio20.60
P/E Growth1.58

Sales & Book Value

Annual Sales$1.47 billion
Price / Sales3.29
Cash Flow$3.62 per share
Price / Cash Flow15.59
Book Value$16.15 per share
Price / Book3.50

Profitability

EPS (Most Recent Fiscal Year)$2.42
Net Income$60.80 million
Net Margins3.99%
Return on Equity16.83%
Return on Assets7.25%

Miscellaneous

Employees4,500
Outstanding Shares85,870,000
Market Cap$4.85 billion
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:IART Rates by TradingView

(Ad)

Join a small community of investors looking for the next big winner. Every Sunday reveals 3 compelling stocks that should be on your radar for the week ahead. Sign up here to see what stocks have made it to our watchlist this week.

Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions

What is Integra Lifesciences' stock symbol?

Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."

When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?

Integra Lifesciences shares split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were distributed to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.

How were Integra Lifesciences' earnings last quarter?

Integra Lifesciences Holdings Corp (NASDAQ:IART) announced its quarterly earnings results on Thursday, October, 24th. The life sciences company reported $0.68 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.65 by $0.03. The life sciences company earned $379.10 million during the quarter, compared to the consensus estimate of $376.85 million. Integra Lifesciences had a return on equity of 16.83% and a net margin of 3.99%. The business's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.59 earnings per share. View Integra Lifesciences' Earnings History.

When is Integra Lifesciences' next earnings date?

Integra Lifesciences is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Integra Lifesciences.

What guidance has Integra Lifesciences issued on next quarter's earnings?

Integra Lifesciences updated its fourth quarter 2019 After-Hours earnings guidance on Tuesday, January, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $395-395 million, compared to the consensus revenue estimate of $397.91 million.

What price target have analysts set for IART?

11 Wall Street analysts have issued 12-month price targets for Integra Lifesciences' stock. Their forecasts range from $50.00 to $75.00. On average, they anticipate Integra Lifesciences' share price to reach $61.91 in the next year. This suggests a possible upside of 9.7% from the stock's current price. View Analyst Price Targets for Integra Lifesciences.

What is the consensus analysts' recommendation for Integra Lifesciences?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Integra Lifesciences.

What are Wall Street analysts saying about Integra Lifesciences stock?

Here are some recent quotes from research analysts about Integra Lifesciences stock:
  • 1. According to Zacks Investment Research, "Integra LifeSciences exited the second quarter of 2019 on a strong note with better-than-expected results. Organic revenue growth was encouraging and was above the company’s expectation. Within global neurosurgery business, sales in dural access and repair increased in low-single digits on an organic basis with growth in both graft and sealant product lines. Benefiting from product launches and an enhanced sales force performance, the company envisions faster organic growth during the second half of 2019. On the flip side, escalating costs and expenses have been a major headwind for Integra Lifesciences. A tough competitive landscape adds to the woes.  Overall, Integra LifeSciences outperformed its industry in the past three months." (9/2/2019)
  • 2. Cantor Fitzgerald analysts commented, "We maintain our Neutral rating and 12-month price target of $50 on IART. Although we view IART’s long-range plan as impressive, we believe execution over the next few quarters is critical to restoring investor confidence in the stock. We think it is appropriate to stay on the sidelines at this time, but we might become more positive on the stock if the company were to execute on its integration and salesforce restructuring goals. We think IART is fairly valued at current levels, appropriately balancing the long-term opportunities with the risk of near-term disruption from the Codman acquisition and the changes to the OTT sales channel structure." (2/21/2019)

Has Integra Lifesciences been receiving favorable news coverage?

Media headlines about IART stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Integra Lifesciences earned a daily sentiment score of -1.6 on InfoTrie's scale. They also assigned news articles about the life sciences company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Integra Lifesciences.

Who are some of Integra Lifesciences' key competitors?

What other stocks do shareholders of Integra Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra Lifesciences investors own include Adobe (ADBE), NVIDIA (NVDA), Advanced Micro Devices (AMD), Intel (INTC), Netflix (NFLX), AbbVie (ABBV), Square (SQ), Activision Blizzard (ATVI), Gilead Sciences (GILD) and GW Pharmaceuticals PLC- (GWPH).

Who are Integra Lifesciences' key executives?

Integra Lifesciences' management team includes the folowing people:
  • Mr. Peter J. Arduini, Pres, CEO & Director (Age 54)
  • Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 76)
  • Mr. Glenn G. Coleman, Corp. VP of International & CFO (Age 51)
  • Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 56)
  • Mr. Robert T. Davis Jr., Corp. VP and Pres of Orthopedics & Tissue Technologies (Age 60)

Who are Integra Lifesciences' major shareholders?

Integra Lifesciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Tributary Capital Management LLC (0.55%), First National Bank of Omaha (0.05%), Nisa Investment Advisors LLC (0.03%), Diversified Trust Co (0.02%), Cardinal Capital Management (0.02%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, John Mooradian, Joseph Vinhais, Keith Bradley, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy, Rhonda Germany Ballintyn, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences.

Which major investors are selling Integra Lifesciences stock?

IART stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Nisa Investment Advisors LLC, State of Alaska Department of Revenue, Cardinal Capital Management and Huntington National Bank. Company insiders that have sold Integra Lifesciences company stock in the last year include Christian S Schade, Daniel L Reuvers, Eric Schwartz, Glenn Coleman, John Mooradian, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy and Richard E Caruso. View Insider Buying and Selling for Integra Lifesciences.

Which major investors are buying Integra Lifesciences stock?

IART stock was acquired by a variety of institutional investors in the last quarter, including Loveless Wealth Management LLC, Orrstown Financial Services Inc., Alpine Global Management LLC, Sciencast Management LP, First National Bank of Omaha, Diversified Trust Co, Exchange Traded Concepts LLC and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill and Rhonda Germany Ballintyn. View Insider Buying and Selling for Integra Lifesciences.

How do I buy shares of Integra Lifesciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Integra Lifesciences' stock price today?

One share of IART stock can currently be purchased for approximately $56.45.

How big of a company is Integra Lifesciences?

Integra Lifesciences has a market capitalization of $4.85 billion and generates $1.47 billion in revenue each year. The life sciences company earns $60.80 million in net income (profit) each year or $2.42 on an earnings per share basis. Integra Lifesciences employs 4,500 workers across the globe.View Additional Information About Integra Lifesciences.

What is Integra Lifesciences' official website?

The official website for Integra Lifesciences is http://www.integralife.com/.

How can I contact Integra Lifesciences?

Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]


MarketBeat Community Rating for Integra Lifesciences (NASDAQ IART)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  393 (Vote Outperform)
Underperform Votes:  474 (Vote Underperform)
Total Votes:  867
MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: What is a Call Option?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel